WebDiabetes mellitus type 1 or 2, and age 40–75 years, with LDL-C 70–189 mg/dL. 10-year ASCVD risk ≥ 7.5%and age 40–75years (see Table 2 for calculation information). ... In selected individuals who are not in the four main statin benefit groups (see Table 5), and for whom a decision to initiate statin ... WebDec 21, 2024 · Patients with diabetes (age 40 to 75, LDL-C 70-180mg/dl) are automatically considered for moderate-intensity statin, but when he or she has an estimated 10-year ASCVD risk factor of ≥7.5%, is a candidate for high-intensity statin. Table 2. Statin Therapy Recommendation Algorithm, per the ACC/AHA. 2.
Statin Use for the Primary Prevention of Cardiovascular Disease in ...
WebNov 1, 2009 · Thus, even in diabetic individuals without other cardiovascular risk factors, a beneficial effect of statins was noted. This outcome may be a result of the pleotropic … WebAug 23, 2024 · The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater. C: ... MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571. 22. Panozzo CA, Curtis LH, Marshall J, et al ... great bend high school wrestling schedule
Statin Use for the Primary Prevention of Cardiovascular Disease in ...
WebThis trial reported a small differential in LDL-C–lowering effect between the statin therapy group and usual care group and showed no benefit of statin use overall. ... MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. ... WebJul 27, 2015 · Among the recommendations was that people 40 to 75 years of age without clinical ASCVD and diabetes should take statins if they have an LDL cholesterol level of 70 to 189 mg/dL and an estimated 10-year ASCVD risk of 7.5% or more. ... Another group led by Drs. Ankur Pandya and Thomas A. Gaziano at the Harvard T.H. Chan School of Public … WebStatins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease.They are the most common cholesterol-lowering drugs. Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and … great bend homicide